biostudies-literatureUnknown11(24)Makita SCelgeneBristol-Myers SquibbThe autologous anti-CD19 chimeric antigen receptor (CAR) T-cell product, lisocabtagene maraleucel (liso-cel), is administered at equal target doses of CD8⁺ and CD4⁺ CAR⁺ T cells. This analysis assessed safety and efficacy of liso-cel in Japanese patients with relapsed or refractory (R/R) aggressive large B-cell lymphoma (LBCL) in Cohort 3 of TRANSCEND WORLD (NCT03484702). Liso-cel (100 × 10⁶ total CAR⁺ T cells) was administered 2-7 days after lymphodepletion. The primary efficacy endpoint was objective response rate (ORR; Lugano 2014 criteria) assessed by an independent review committee. Fourteen patients were enrolled; 10 received liso-cel infusion (median time to liso-cel availability, 23 days) and were evaluable at data cutoff (mediCancer medicine4889-4899https://www.ebi.ac.uk/biostudies/studies/S-EPMC9761090biostudies-literaturePhase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.PMC9761090Stepan LRettby NIzutsu KAnanthakrishnan RYamamoto GOgasawara KMakita SAsano-Mori YKaji DSchusterbauer CMaruyama DHasskarl JfalsePhase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell product, lisocabtagene maraleucel (liso-cel), is administered at equal target doses of CD8⁺ and CD4⁺ CAR⁺ T cells. This analysis assessed safety and efficacy of liso-cel in Japanese patients with relapsed or refractory (R/R) aggressive large B-cell lymphoma (LBCL) in Cohort 3 of TRANSCEND WORLD (NCT03484702). Liso-cel (100 × 10⁶ total CAR⁺ T cells) was administered 2-7 days after lymphodepletion. The primary efficacy endpoint was objective response rate (ORR; Lugano 2014 criteria) assessed by an independent review committee. Fourteen patients were enrolled; 10 received liso-cel infusion (median time to liso-cel availability, 23 days) and were evaluable at data cutoff (medi2022-01-01T00:00:00Z2022 Dec2025-04-26T00:48:11.77Z2025-04-06T09:49:36.368ZS-EPMC97610903561932510.1002/cam4.4820